On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter 2025 adjusted earnings of 78 cents, compared to 60 cents a year ago, beating the consensus of 57 cents.
Pfizer’s sales jumped 10% year over year to $14.70 billion, above the consensus of $13.41 billion, reflecting an operational increase of 10%.
The operational increase was primarily driven by an increase in revenues for the Vyndaqel family, Comirnaty, Paxlovid, Padcev, Eliquis, and several other products across categories, despite the unfavorable impact of higher manufacturer discounts resulting from the Inflation Reduction Act (IRA) Medicare Part D Redesign.
Also Read: Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlook
Heart drug Vyndaqel family sales increased 21% operationally, to $1.62 billion.
Comirnaty sales were $381 million, up 95% operationally, and Paxlovid sales were up …